221 related articles for article (PubMed ID: 11113116)
1. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product.
Mulligan-Kehoe MJ; Wagner R; Wieland C; Powell R
J Biol Chem; 2001 Mar; 276(11):8588-96. PubMed ID: 11113116
[TBL] [Abstract][Full Text] [Related]
2. A truncated plasminogen activator inhibitor-1 protein blocks the availability of heparin-binding vascular endothelial growth factor A isoforms.
Mulligan-Kehoe MJ; Kleinman HK; Drinane M; Wagner RJ; Wieland C; Powell RJ
J Biol Chem; 2002 Dec; 277(50):49077-89. PubMed ID: 12381729
[TBL] [Abstract][Full Text] [Related]
3. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
4. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
[TBL] [Abstract][Full Text] [Related]
5. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
6. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
7. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
8. [Mechanism of inhibitory effect of angiostatin on plasminogen activation by its physiologic activators].
Aĭsina RB; Mukhametova LI; Prisiazhnaia NV; Gulin DA; Levashov MIu; Gershkovich KB
Bioorg Khim; 2011; 37(3):319-26. PubMed ID: 21899046
[TBL] [Abstract][Full Text] [Related]
9. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor.
Kost C; Benner K; Stockmann A; Linder D; Preissner KT
Eur J Biochem; 1996 Mar; 236(2):682-8. PubMed ID: 8612645
[TBL] [Abstract][Full Text] [Related]
10. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin.
Sorrell AM; Shand JH; Tonner E; Gamberoni M; Accorsi PA; Beattie J; Allan GJ; Flint DJ
J Biol Chem; 2006 Apr; 281(16):10883-9. PubMed ID: 16505491
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic activity of rPAI-1(23) promotes vasa vasorum regression in hypercholesterolemic mice through a plasmin-dependent mechanism.
Mollmark J; Ravi S; Sun B; Shipman S; Buitendijk M; Simons M; Mulligan-Kehoe MJ
Circ Res; 2011 Jun; 108(12):1419-28. PubMed ID: 21546607
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of angiostatins on activity of the plasminogen/plasminogen activator system.
Aisina RB; Mukhametova LI; Gulin DA; Levashov MY; Prisyazhnaya NV; Gershkovich KB; Varfolomeyev SD
Biochemistry (Mosc); 2009 Oct; 74(10):1104-13. PubMed ID: 19916923
[TBL] [Abstract][Full Text] [Related]
14. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.
D'Amico S; Martial JA; Struman I
FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964
[TBL] [Abstract][Full Text] [Related]
15. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).
Takada Y
J Biomed Biotechnol; 2012; 2012():136302. PubMed ID: 23125522
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
17. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
Stack MS; Gately S; Bafetti LM; Enghild JJ; Soff GA
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):77-84. PubMed ID: 10229661
[TBL] [Abstract][Full Text] [Related]
18. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
19. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
[TBL] [Abstract][Full Text] [Related]
20. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin.
Fa M; Karolin J; Aleshkov S; Strandberg L; Johansson LB; Ny T
Biochemistry; 1995 Oct; 34(42):13833-40. PubMed ID: 7577977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
